



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/812,238	03/29/2004	Kishore K. Wary	D6563	3362

7590 12/28/2004  
Dr. Benjamin Adler  
ADLER & ASSOCIATES  
8011 Candle Lane  
Houston, TX 77071

EXAMINER

NGUYEN, QUANG

ART UNIT	PAPER NUMBER
----------	--------------

1636

DATE MAILED: 12/28/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

**Application No.**

10/812,238

**Applicant(s)**

WARY ET AL.

**Examiner**

Quang Nguyen, Ph.D.

**Art Unit**

1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-41 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-41 are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_.

### **DETAILED ACTION**

Claims 1-41 are pending in the present application, and they are subjected to the following restrictions.

### ***Election/Restrictions***

Restriction to one of the following inventions is required under 35 U.S.C. 121:

#### ***Group Restriction***

- I. Claims 1-7, 25-26 and 37-41, drawn to a method of enhancing cell-cell interaction, comprising the step of expressing in a cell a vascular endothelial growth factor and type I collagen inducible protein (VCIP) having the sequence of SEQ ID NO:13; a method of enhancing cell-cell adhesion junction formation in a patient or enhancing angiogenesis in a patient comprising the step of administering to said patient a vector encoding VCIP; and a vector comprising nucleotide sequence that encodes the same, classified in class 514, subclass 44.
- II. Claims 10-11, 16-17 and 27-33, drawn to a method of inhibiting cell-cell interaction or treating a patient having a pathological condition resulting from integrin-mediated cell-cell interaction or inhibiting angiogenesis and the formation of capillaries in a patient, the method comprising the step of blocking the binding of integrins to VCIP by an antibody directed against a peptide derived from VCIP; an antibody directed against a peptide derived

from VCIP and a diagnostic kit comprising the same antibody, classified in class 424, subclass 130.1.

III. Claims 12-13, 18-19, 22-24 and 34-35, drawn to a method of inhibiting cell-cell interaction or treating a patient having a pathological condition resulting from integrin-mediated cell-cell interaction or inhibiting angiogenesis and the formation of capillaries in a patient, the method comprising the step of blocking the binding of integrins to VCIP by a peptide derived from VCIP; a peptide derived from VCIP, classified in class 424, subclass 94.1.

IV. Claim 36, drawn to a method of inhibiting angiogenesis and the formation of capillaries in a patient, the method comprising the step of administering to said patient a pharmacological effective amount of antisense oligonucleotides against the transcripts encoding VCIP, classified in class 514, subclass 44.

Claims 8-9, 14, 15 and 20-21 link a plurality of distinct inventions of Groups II-IV. This is because a method of inhibiting cell-cell interaction or treating a patient having a pathological condition resulting from integrin-mediated cell-cell interaction or inhibiting angiogenesis and the formation of capillaries in a patient comprising the step of blocking the binding of integrins to VCIP using an agent encompassing an antibody directed against a peptide derived from VCIP (Group II), a peptide derived from VCIP (Group III), and antisense oligonucleotides against the transcripts encoding VCIP (Group IV), which

Art Unit: 1636

are distinct chemically, structurally and biochemically. Additionally, there is no substantial common core structure shared among the aforementioned agents.

Upon the allowance of the linking claims, the restriction requirement as to the linked invention shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims or the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-132 (CCPA 1971). See also MPEP 804.01.

The inventions are distinct, each from the other because of the following reasons:

Inventions I to IV are drawn to distinct methods that have different starting materials without any substantial common core structure (e.g., a vector encoding VCIP for Group I, an antibody directed against a peptide derived from VCIP of Group II, a peptide derived from VCIP of Group III, and antisense oligonucleotides against the transcripts encoding VCIP of Group IV) and different technical considerations for achieving the desired results. Additionally, the desired end-result for the method of Group I (enhancing cell-cell interaction) is opposite to that for the methods of Groups II-

Art Unit: 1636

IV (e.g., inhibiting cell-cell interaction). Furthermore, the composition in each Group is not required for any other Groups.

Searching and examining the inventions of Groups I-IV would impose a serious burden since a search for the invention of any Group would not reveal the same starting materials and desired end-results of the other Groups for the reasons already set forth in the preceding paragraph. Therefore, it would be unduly burdensome for the examiner to perform a complete search of the defined areas in both the patent and non-patent literature, and/or consider the patentability of all the inventions in a single application. Therefore, restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

### ***Species Restriction***

**A. Should Applicants elect the invention of Group I,** this application contains claims directed to the following patentably distinct species of the claimed invention:

**A specifically named biological process listed in the Markush group of claim 7.**

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, at least claims 1-7 and 37-39 are generic.

**B. Should Applicants elect one of the inventions of Groups II-IV, this**  
application contains claims directed to the following patentably distinct species of the claimed invention:

**A specifically named biological process listed in the Markush group of claim 14 or claim 20.**

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, at least claims 8-20 are generic.

Additionally, this application contains claims directed to the following patentably distinct species of the claimed invention:

**A specifically named pathological condition listed in the Markush group of claim 21.**

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, at least claims 15-19 and 21 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims

Art Unit: 1636

readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Quang Nguyen, Ph.D., whose telephone number is (571) 272-0776.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's mentor, David Guzo, Ph.D., may be reached at (571) 272-0767, or SPE, Irem Yucel, Ph.D., at (571) 272-0781.

**To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1636; Central Fax No. (571) 273-8300.**



Art Unit: 1636

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Quang Nguyen, Ph.D.

A handwritten signature in black ink, appearing to read 'Quang Nguyen', with a stylized, flowing script.